MCRB vs. STOK, CGEM, AUTL, VALN, XERS, MAZE, TECX, MGTX, MLYS, and TRDA
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Stoke Therapeutics (STOK), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Valneva (VALN), Xeris Biopharma (XERS), Maze Therapeutics (MAZE), Tectonic Therapeutic (TECX), MeiraGTx (MGTX), Mineralys Therapeutics (MLYS), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry.
Seres Therapeutics vs.
Stoke Therapeutics (NASDAQ:STOK) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
Stoke Therapeutics has higher earnings, but lower revenue than Seres Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics received 415 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 75.66% of users gave Stoke Therapeutics an outperform vote while only 71.72% of users gave Seres Therapeutics an outperform vote.
Stoke Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.
Stoke Therapeutics presently has a consensus price target of $23.00, suggesting a potential upside of 176.11%. Seres Therapeutics has a consensus price target of $5.08, suggesting a potential upside of 532.65%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Stoke Therapeutics.
Seres Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. Seres Therapeutics' return on equity of 0.00% beat Stoke Therapeutics' return on equity.
In the previous week, Stoke Therapeutics had 17 more articles in the media than Seres Therapeutics. MarketBeat recorded 25 mentions for Stoke Therapeutics and 8 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.35 beat Stoke Therapeutics' score of 0.27 indicating that Seres Therapeutics is being referred to more favorably in the news media.
59.3% of Seres Therapeutics shares are held by institutional investors. 11.3% of Stoke Therapeutics shares are held by insiders. Comparatively, 5.1% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Seres Therapeutics beats Stoke Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MCRB) was last updated on 2/22/2025 by MarketBeat.com Staff
